Myria Biosciences pioneers GEMMS (Genetically Engineered Modular Molecule Scaffolds), a new class of therapeutic molecules that combines the most important features of small molecules and biologics, the two work horses of the pharmaceutical industry, into one. Myria’s platform uses computational data mining, synthetic biology and high-throughput experimentation to design, produce and test millions of novel molecules, and provides innovative drug candidates for diseases where other drugs have failed to deliver.
Location: Switzerland, Basel-City, Basel
Employees: 1-10
Founded date: 2022
Mentions in press and media 3
| Date | Title | Description |
| 21.08.2024 | The Future of Safety and Sustainability: Innovations in Automotive and Health Tech | In a world where technology evolves at lightning speed, two sectors are racing ahead: automotive safety and health tech. Companies like Altair and Oasys are reshaping the landscape of crash simulations, while Swiss startups are pushing the ... |
| 20.08.2024 | Prominent programs support Swiss startups | Myria Biosciences, a Basel-based startup at the forefront of AI-driven drug discovery, has recently joined the NVIDIA Inception Program, a significant milestone that will accelerate their efforts to revolutionize the pharmaceutical industr... |
| 21.06.2024 | Attracting investors with AI, synthetic biology and high-troughput screening | Basel-based startup Myria Biosciences advances drug discovery using synthetic biology and AI. Its Genetically Engineered Modular Molecular Scaffolds (GEMMS) platform combines synthetic biology, AI and high-throughput screening at unprecede... |